Browsing Harvard Law School by Keyword "ImClone"
Now showing items 1-2 of 2
-
Disclosure of the Dealings Between Drug Developing Companies and the FDA Under the Federal Securities Laws
(2002)The purpose of this article is to highlight the main issues raised by the Food and Drug Administration’s (“FDAâ€) approval process relating to new drugs and the treatment ... -
Placebo or Panacea: The FDA's Rejection of ImClone's Erbitux Licensing Application
(2003)This paper draws upon the media reports, congressional hearing testimony, and company press releases to recount events surrounding the FDA’s refusal to issue a license to ImClone’s ...